NeuroSense Announces $600,000 Insider-Led PIPE Financing at Premium Pricing

On April 28, 2026, NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced the pricing of an insider-led private placement (PIPE) financing totaling $600,000. The company entered into a definitive agreement to sell 750,000 ordinary shares at a price of $0.80 per share, which represents a 6.7% premium over the closing price on April 27, 2026. The financing was led by Chief Executive Officer Alon Ben-Noon and Chief Financial Officer Or Eisenberg, both of whom committed $200,000, alongside a $200,000 commitment from an existing significant shareholder. The transaction is subject to customary closing conditions and is expected to close during the week of May 3, 2026. NeuroSense intends to use the net proceeds for general corporate purposes as it approaches upcoming clinical and regulatory milestones. The company is currently a late-clinical stage biotech focused on neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's. The securities are being issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act.